Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), represents a novel therapeutic approach in the treatment of Parkinson’s disease. Unlike traditional treatments that focus on managing symptoms, Risvodetinib targets the underlying biological mechanisms driving disease progression.
Risvodetinib’s mechanism of action offers the potential for disease modification in Parkinson’s disease patients. By restoring neuroprotective mechanisms through Abl kinase inhibition, Risvodetinib seeks to not only halt disease progression but also reverse functional loss associated with the condition.
The ongoing 201 Trial evaluates the safety, tolerability...
